Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M73,269Revenue (TTM) $M23,002Net Margin (%)15.4Altman Z-Score1.7
Enterprise Value $M77,573EPS (TTM) $1.4Operating Margin %21.6Piotroski F-Score6
P/E(ttm)21.3Beneish M-Score-2.4Pre-tax Margin (%)15.7Higher ROA y-yY
Price/Book4.910-y EBITDA Growth Rate %-6.7Quick Ratio0.7Cash flow > EarningsY
Price/Sales3.35-y EBITDA Growth Rate %-12.8Current Ratio0.9Lower Leverage y-yY
Price/Free Cash Flow40.1y-y EBITDA Growth Rate %16.8ROA % (ttm)5.6Higher Current Ratio y-yN
Dividend Yield %4.8PEG--ROE % (ttm)23.7Less Shares Outstanding y-yN
Payout Ratio %144Shares Outstanding M2,530ROIC % (ttm)17.4Gross Margin Increase y-yY

Gurus Latest Trades with AZN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

AZN is held by these investors:



AZN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ASTRAZENECA PLC10% Owner 2014-11-12Sell2,000,000$1770.65view

Quarterly/Annual Reports about AZN:

    News about AZN:

    Articles On GuruFocus.com
    Dodge & Cox Comments on AstraZeneca Feb 06 2017 
    Dodge & Cox's Stock Fund 4th Quarter Commentary Jan 16 2017 
    Big Alzheimer Flop Creates Buying Opportunity for Eli Lilly Dec 10 2016 
    8 Uncommon Stocks NWQ Managers Is Buying Dec 06 2016 
    How Could a Potential Nexium Lawsuit Affect AstraZeneca? Nov 03 2016 
    Novo Nordisk Is Being Ignored Oct 06 2016 
    Novartis Is Surviving Oct 03 2016 
    10 Stocks Dodge & Cox Keep Buying Sep 22 2016 
    Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
    Francis Chou Raises Stake in Resolute Forest Products Mar 20 2016 

    More From Other Websites
    $250M deal: AstraZeneca sells rights to cancer therapy Feb 21 2017
    The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan,... Feb 21 2017
    Sanofi’s Unique Foothold in Diabetes and Cardiovascular Feb 20 2017
    4:16 am AstraZeneca reports Phase III trial for Lynparza meets primary endpoint Feb 20 2017
    AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink Feb 17 2017
    Clovis, Tesaro Soar on Astrazeneca Phase Three News Feb 17 2017
    FTSE gains for third week as Unilever rises, Coca Cola HBC sets record Feb 17 2017
    European Benchmarks Fall, But London Bucks Trend on Takeover Activity Feb 17 2017
    [$$] AstraZeneca boosted by positive breast cancer trial Feb 17 2017
    AstraZeneca's Lynparza meets main goal in breast cancer study Feb 17 2017
    AstraZeneca Stock Rises On Successful Breast Cancer Drug Trial Feb 17 2017
    Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ Feb 17 2017
    LYNPARZA™ (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast... Feb 17 2017
    Britain's FTSE set for week of modest gains, pharmas lead Feb 17 2017
    Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook Feb 17 2017
    Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook Feb 16 2017
    Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook Feb 16 2017
    Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook Feb 16 2017
    Why This FDA Approval for Valeant Is Not as Good as First Thought Feb 16 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)